SCHEMBL14728290

SCHEMBL14728290

CC(C)(C)OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 2/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.44
GLA P06280 1/20 0.44
BRCA1 P38398 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28513329 1.00 TSHR (0.49) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL27443069 1.00 TSHR (0.49) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL24255365 1.00 TSHR (0.49) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL2575940 1.00 TSHR (0.49) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL26813489 0.99 TSHR (0.50) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL22515359 0.93 TSHR (0.44) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL12801230 0.91 KMT2A (0.50) TSHRSMN1; SMN2HSD17B10TDP1HPGD
SCHEMBL21070783 0.91 POLB (0.48) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL21071168 0.91 POLB (0.48) TSHRSMN1; SMN2HSD17B10POLBAPEX1
SCHEMBL21070555 0.91 POLB (0.48) TSHRSMN1; SMN2HSD17B10POLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030833-B2 Method for producing hetero-type monodisperse polyethylene glycol derivative NOF CORPORATION (JP) 2024-07-09 US disclosed
US-20230131121-A1 BRANCHED DISCRETE PEG CONSTRUCTS AUDAX PRIVATE DEBT LLC, AS AGENT 2023-04-27 US disclosed
US-20170313656-A1 Branched Discrete PEG Constructs QUANTA BIODESIGN, LTD. 2017-11-02 US disclosed
US-20170313656-A1 Branched Discrete PEG Constructs QUANTA BIODESIGN, LTD. 2017-11-02 US disclosed
US-20130052130-A1 Branched Discreet PEG Constructs UNIVERSITY OF WASHINGTON (US) 2013-02-28 US disclosed
US-20130052130-A1 Branched Discreet PEG Constructs UNIVERSITY OF WASHINGTON (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313656-A1 Branched Discrete PEG Constructs BTD, IDUA, DNPEP TSHR 1248/4885SMN1; SMN2 3563/4885HSD17B10 1069/4885
US-20230131121-A1 BRANCHED DISCRETE PEG CONSTRUCTS BTD, IDUA, DNPEP TSHR 1305/4885SMN1; SMN2 3691/4885HSD17B10 1052/4885
US-12030833-B2 Method for producing hetero-type monodisperse polyethylene glycol derivative DDT, DDC, FGFR2 TSHR 4081/4885SMN1; SMN2 3732/4885HSD17B10 824/4885
US-20130052130-A1 Branched Discreet PEG Constructs BTD, DNPEP, IDUA TSHR 1649/4885SMN1; SMN2 3611/4885HSD17B10 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.